Papillorenal syndrome secondary prevention

Jump to navigation Jump to search

Papillorenal syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Papillorenal syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Papillorenal syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Papillorenal syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Papillorenal syndrome secondary prevention

CDC on Papillorenal syndrome secondary prevention

Papillorenal syndrome secondary prevention in the news

Blogs on Papillorenal syndrome secondary prevention

Directions to Hospitals Treating Papillorenal syndrome

Risk calculators and risk factors for Papillorenal syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Secondary Prevention

Management of the disease should be focused on preventing end-stage renal disease (ESRD) and/or vision loss. The treatment of hypertension may also preserve renal function. Renal replacement therapy is recommended, and vision experts may provide assistance to adapt to continued vision loss.[1]

References

  1. Pagon RA, Bird TD, Dolan CR; et al. PMID 20301624. Missing or empty |title= (help)

Template:WH Template:WS